Central giant cell granuloma

Central giant cell granuloma (CGCG) is a benign, locally aggressive intraosseous lesion of the jaws composed of cellular fibrous tissue containing multinucleated giant cells, hemorrhagic foci, and hemosiderin deposits.[1] The WHO defines it as an osteolytic lesion of uncertain etiology; proposed contributing factors include local trauma, intraosseous hemorrhage, inflammation, and genetic abnormalities, though none is established as a definitive cause.[1][2] CGCG accounts for up to 7% of benign tumors of the jaws and is subdivided into non-aggressive and aggressive subtypes based on clinical and radiographic behavior rather than histology.[2][3] The signature radiographic pattern is a well-defined, expansile radiolucency that may be unilocular or multilocular. Management ranges from curettage to resection, with pharmacologic adjuncts increasingly used for aggressive or recurrent lesions.[4][5]

The current accepted designation is central giant cell granuloma (CGCG), also termed central giant cell lesion (CGCL).[3] Jaffe originally described this entity in 1953 as "giant cell reparative granuloma"; the qualifier "reparative" was subsequently abandoned after recognition that many lesions behave aggressively and are not reparative in nature.[3] The term "giant cell reparative granuloma" (GCRG) persists in some radiology and pathology literature and should be considered synonymous.[6][7] CGCG must be distinguished terminologically from peripheral giant cell granuloma (PGCG), which arises in the gingival soft tissue, and from giant cell tumor of bone (GCTB), a distinct neoplasm with different molecular underpinnings.[2][8]

• Age: Predominantly affects patients younger than 30 years, though cases occur across a wide age range.[1][9]
• Sex: Female predilection, approximately 2:1.[1][10]
• Frequency: Rare; represents up to 7% of benign jaw tumors.[3]
• Jaw distribution: The mandible is more commonly affected than the maxilla. The anterior mandible (premolar–incisor region) is the classic site, with a predilection for the tooth-bearing area. A large retrospective series found the posterior mandible (42%) and posterior maxilla (21%) most frequently involved. Approximately 35% of mandibular lesions cross the midline.[1][10][11]
• Aggressive behavior: Aggressive clinical features are present in roughly 19% of cases.[3]

Presentation and symptoms

• Non-aggressive CGCG: Typically asymptomatic and discovered incidentally on routine dental radiographs. Growth is slow, and facial swelling, when present, develops gradually.[1][2]
• Aggressive CGCG: Presents with pain, rapid swelling, paresthesia or numbness of the inferior alveolar nerve distribution, loose or displaced teeth, and mucosal bleeding. Facial asymmetry may be pronounced.[2][3]

Examination findings

• Firm, non-tender to tender bony expansion of the alveolar ridge or body of the jaw.
• Overlying mucosa is usually intact but may appear bluish-purple when the cortex is thinned or perforated.
• Tooth mobility and displacement of developing tooth germs are common in younger patients.[3]

Tempo and complications

Non-aggressive lesions may remain stable for months to years. Aggressive lesions grow rapidly and can cause cortical perforation, pathologic fracture (rare), and significant functional or aesthetic compromise.[2][9] Paresthesia of the lip has been reported in a minority of cases.[11]

Location and distribution

CGCG arises centrally within the jaw bones. The anterior mandible—premolar to premolar region—is the classic location, and lesions frequently cross the midline.[11] The anterior maxilla is the next most common site.[1] Posterior jaw involvement occurs but is less characteristic. Maxillary lesions may extend into the maxillary sinus or nasal floor.[12]

Periphery and shape

• Margins are well-defined in the majority of cases (approximately 65–86%).[10][11]
• The periphery may be corticated or non-corticated; non-corticated margins are more common in aggressive lesions.[11][13]
• Scalloped borders are seen in roughly half of cases and may produce a lobulated outline.[11]
• Shape is typically round to ovoid; larger lesions become irregular.

Internal architecture

• The internal pattern is radiolucent; both unilocular and multilocular configurations occur.[1][12]
• Smaller lesions tend to be unilocular; larger lesions (>5 cm) are more often multilocular with thin bony septa producing a soap-bubble or honeycomb pattern.[11][12]
• Wispy internal opacification or faint trabeculation is present in approximately half of cases, reflecting residual bone trabeculae or osteoid within the lesion.[11]
• Fluid-fluid levels, reflecting hemorrhagic or cystic components, are occasionally identified on cross-sectional imaging.[12]

Effects on teeth and adjacent structures

• Tooth displacement: Occurs in approximately 50% of cases, including displacement of developing tooth germs in children.[3][11]
• Root resorption: Reported in roughly 37% of cases; smooth, pressure-type external resorption is typical and favors an aggressive subtype.[2][11]
• Tooth vitality: Adjacent teeth generally remain vital unless secondarily involved.
• Inferior alveolar canal: May be displaced inferiorly or resorbed.

Cortical involvement and extent

• Cortical expansion is the hallmark growth pattern, with thinning and remodeling of the buccal and/or lingual cortex.[12][14]
• Cortical perforation occurs in approximately 50% of cases and is a criterion for aggressive behavior.[2][11]
• Aggressive lesions may extend into adjacent soft tissues.
• In the maxilla, extension into the maxillary sinus, nasal cavity, or orbital floor may occur.[12]
• CBCT demonstrates the three-dimensional extent of cortical thinning, perforation, and internal septa more accurately than panoramic radiography, aiding surgical planning and assessment of the buccal-lingual dimension.[12][14]

Variants

• Aggressive versus non-aggressive: Aggressive lesions are defined by size >5 cm, rapid growth, pain, paresthesia, root resorption, cortical perforation, or recurrence after curettage. Non-aggressive lesions are smaller, slow-growing, and show less cortical and dental involvement.[1][2][3]
• Hybrid CGCG: CGCG may coexist with other jaw lesions (central odontogenic fibroma, central ossifying fibroma, fibrous dysplasia), altering the expected radiographic appearance. Hybrid lesions are most often well-defined, radiolucent, and located in the posterior mandible.[13]

CT (medical)

On medical CT, CGCG appears as an expansile, osteolytic mass of heterogeneous soft-tissue attenuation with cortical thinning and remodeling.[12][14] Thin internal septa and a soft-tissue component are characteristic. Lesions may show areas of higher attenuation corresponding to hemorrhage, hemosiderin, or osteoid formation.[14] Cortical perforation and soft-tissue extension are well delineated.

MRI

The solid component of CGCG is typically isointense on T1-weighted images and characteristically hypointense on T2-weighted images, a feature attributed to hemosiderin deposition and high cellularity.[12][15] Cystic or hemorrhagic areas produce variable T1 and T2 signal. Fluid-fluid levels, reflecting secondary aneurysmal bone cyst–like change, are present in a minority of cases.[12] Enhancement is heterogeneous within the solid component, with rim enhancement of cystic locules.[12][15] The T2 hypointensity of the solid component is a useful discriminator from many other jaw lesions and should raise suspicion for a giant cell–containing lesion.[12]

CGCG must be distinguished from other radiolucent, expansile jaw lesions, particularly those containing giant cells. Serum calcium and parathyroid hormone should be obtained in every case to exclude brown tumor. Biopsy is required for definitive diagnosis because imaging features overlap substantially among these entities.

The highest-risk diagnostic pitfall is failure to exclude hyperparathyroidism: brown tumor is histologically indistinguishable from CGCG, and the diagnosis hinges entirely on biochemical evaluation. Serum calcium and intact PTH should be obtained before any surgical intervention.[3][16]

Microscopic findings

CGCG is characterized by a cellular fibrous stroma containing multinucleated osteoclast-like giant cells admixed with round, oval, and spindle-shaped mononuclear stromal cells.[1][22] The giant cells tend to aggregate in clusters, often near areas of hemorrhage, rather than being uniformly dispersed—a pattern that helps distinguish CGCG from GCTB, in which giant cells are homogeneously distributed.[17] The stroma is richly vascularized and contains abundant hemorrhagic foci with hemosiderin deposits.[1][22] Reactive new bone or osteoid trabeculae may be present at the lesion periphery.

Aggressive versus non-aggressive subtypes

No reliable histologic criteria distinguish aggressive from non-aggressive CGCG; the subtype classification is based on clinical and radiographic features.[3][22] Immunohistochemical studies show higher expression of proliferative (Ki-67), osteoclastic (cathepsin D), and stromal activation markers (α-SMA, CSF-1R, CD163) in aggressive and recurrent lesions, suggesting a more active macrophage-osteoclast-stroma microenvironment.[23]

Radiologic-pathologic correlation

The multiloculated radiolucent pattern corresponds to expansile fibrovascular tissue with giant cell aggregates separated by thin bony septa. Internal opacification reflects osteoid or residual bone trabeculae within the lesion. Fluid-fluid levels on imaging correspond to secondary hemorrhagic cystic change.

Molecular findings relevant to diagnosis

• Somatic gain-of-function mutations in KRAS, FGFR1, or TRPV4 are identified in approximately 72% of sporadic CGCG, converging on MAPK pathway activation.[24][25]
• H3F3A mutations are absent in CGCG, distinguishing it from GCTB.[2]
• USP6 rearrangement is absent, distinguishing CGCG from aneurysmal bone cyst.[2]
• These molecular markers have direct diagnostic utility when histology alone is equivocal.[2][24]

Workup

• Serum calcium and intact PTH to exclude hyperparathyroidism.[3][16]
• Incisional biopsy for histopathologic confirmation.
• Cross-sectional imaging (CBCT or medical CT) to define extent, cortical integrity, and relationship to vital structures before treatment planning.[12]

Surgical treatment

• Curettage is the most common first-line treatment for non-aggressive lesions. Recurrence rates after curettage range from 10% to 50%, with higher rates in aggressive lesions.[3]
• En bloc resection is reserved for large, aggressive, or recurrent lesions and carries a lower recurrence rate but greater morbidity, including loss of jaw continuity and need for reconstruction.[4][9]
• A European multicenter study reported an overall recurrence rate of 15.8% with a mean follow-up of 41 months across mixed surgical approaches.[9]

Pharmacologic therapy

• Intralesional corticosteroids (triamcinolone acetonide): Induce fibrosis and giant cell apoptosis; effective in reducing lesion size, though approximately 40% of patients require supplemental surgery.[5][26]
• Calcitonin (subcutaneous or intranasal): Inhibits osteoclast-mediated resorption; complete remission reported in roughly half of treated patients.[5]
• Denosumab (subcutaneous RANKL inhibitor, 120 mg): Emerging evidence supports its use as neoadjuvant therapy to reduce lesion size and promote ossification before surgery, or as definitive treatment in select cases. Clinical and radiologic response has been observed in all treated patients in recent series. Adverse effects include hypocalcemia and rebound hypercalcemia upon discontinuation.[4][27]
• Interferon-alpha: Used in refractory cases but carries a higher side-effect burden.[5]

Recurrence and surveillance

• Overall recurrence is approximately 15–33%, with aggressive lesions at highest risk.[3][9][28]
• Radiographic follow-up is recommended for at least 5 years after treatment.[9]
• Recurrent lesions show higher expression of proliferative and stromal activation markers, suggesting a biologically more active microenvironment.[23]

Syndromic associations

CGCG-like giant cell lesions of the jaws occur in several genetic syndromes, and multifocal or bilateral jaw lesions should prompt evaluation for:

• Noonan syndrome and other RASopathies: Germline mutations in the RAS-MAPK pathway (e.g., PTPN11, SOS1) can produce jaw giant cell lesions clinically and histologically identical to sporadic CGCG.[3][8]
• Cherubism: Bilateral, symmetric giant cell lesions of the jaws caused by SH3BP2 mutations; onset in early childhood with characteristic facial fullness.[8][29]
• Neurofibromatosis type 1 (Jaffe-Campanacci syndrome): Giant cell lesions may occur in the jaws alongside café-au-lait macules and neurofibromas.[3][8]
• Hyperparathyroidism: Brown tumors are histologically indistinguishable from CGCG; biochemical screening is mandatory in every case.[3][16]

Pediatric considerations

CGCG has a predilection for children and young adults. In the developing dentition, lesions frequently displace tooth germs and may interfere with eruption. Treatment planning must balance recurrence risk against preservation of developing teeth and jaw growth potential. Pharmacologic approaches (intralesional steroids, denosumab) may be particularly valuable in this population to minimize surgical morbidity.[4][5]